Skip to content
SUM149PT
Tissue
乳房
Disease
乳腺炎性癌
Synonyms
SUM-149PT, SUM 149PT, SUM149-PT, SUM149, SUM-149, SUM 149, 149 PT, 149PT, BrCL12

Documents

SUM149PT

Cell line · Product number 300609

The SUM149PT cell line is derived from a human inflammatory breast carcinoma (IBC), which represents an aggressive subtype of breast cancer. IBC is charac...

US$550.00excl. tax and shipping
In stock
Lot
Recommended (freshest lot)
  • CoA
  • CoA
1

01General information

Description

SUM149PT 細胞系源自人類炎性乳腺癌(IBC),這是一種侵襲性強的乳腺癌亞型。IBC 的特徵在於進展迅速、早期轉移及預後不良。 SUM149PT 細胞被歸類為三陰性乳癌(TNBC),其不表達雌激素受體(ER)、黃體素受體(PR)及 HER2 受體,因此對內分泌治療或 HER2 抑制劑等常見的標靶療法無反應。 因此,此類癌症的治療通常採用細胞毒性化療,儘管這些癌症往往會隨時間發展出抗藥性。

值得注意的是,SUM149PT 細胞攜帶 2288delT BRCA1 突變,導致 BRCA1 功能喪失。此突變屬於移碼缺失,會導致 BRCA1 蛋白質過早終止,從而損害 DNA 修復並促進基因組不穩定性,這正是 BRCA1 突變型癌症的標誌性特徵。 BRCA1 的喪失加劇了 SUM149PT 中觀察到的染色體不穩定性,該細胞系呈現出眾多染色體畸變。除了突變之外,SUM149PT 中的 BRCA1 基因座亦已缺失,進一步加劇了對基因組穩定性的影響。

令人驚訝的是,SUM149PT 細胞中存在一類 CD44+/CD24-/Low 的幹細胞樣癌細胞亞群,該亞群富含癌症幹細胞(CSC)的特性,例如增強的侵襲性、腫瘤形成能力以及對化療的耐藥性。 這些幹細胞樣細胞亦與中心體擴增及循環蛋白 E/Cdk2 活性升高有關。 在 SUM149PT 中抑制 Cdk2 可選擇性地針對這群 CSC 亞群,並恢復其對化療的部分敏感性,這表明針對 Cdk2 的聯合治療策略與傳統化療結合,可能對治療化療抗性 IBC 有效。

Tissue
乳房
Disease
乳腺炎性癌
Synonyms
  • SUM-149PT
  • SUM 149PT
  • SUM149-PT
  • SUM149
  • SUM-149
  • SUM 149
  • 149 PT
  • 149PT
  • BrCL12

02Classification

Organism
Human
Sex
Female
Growth properties
Adherent

03Characteristics

Morphology
上皮性

04Identifiers

Citation
SUM149PT(Cytion 型號 300609)
NCBI TaxID
9606
Cellosaurus
CVCL_3422

05Expression and susceptibility

Protein expression
P53 陽性

06Handling and culture

Culture medium
Ham's F12,含:1.0 mM 穩定型谷氨醯胺、1.0 mM 丙酮酸鈉、1.1 g/L NaHCO₃(Cytion 產品編號 820600a)
Incubation atmosphere

37°C,5% CO₂,加濕環境。

Supplements
在培養基中加入 10% 的胎牛血清(FBS)
Dissociation reagent
Accutase
Subculturing
從貼壁細胞中移除舊培養基,並用不含鈣和鎂的PBS洗滌細胞。T25培養瓶使用3-5毫升PBS,T75培養瓶則使用5-10毫升。 接著,用 Accutase 完全覆蓋細胞,T25 培養瓶使用 1–2 毫升,T75 培養瓶則使用 2.5 毫升。將細胞於室溫下孵育 8–10 分鐘,使其脫附。 孵育後,將細胞與 10 毫升培養基輕柔混合以使其重新懸浮,然後以 300xg 離心 3 分鐘。棄去上清液,將細胞重新懸浮於新鮮培養基中,並轉移至已預先加入新鮮培養基的新培養瓶中。
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

  7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

  8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

07Quality control and cryopreservation

Sterility

透過基於 PCR 的檢測及基於發光原理的支原體檢測方法,排除支原體污染的可能性。

為確保無細菌、真菌或酵母菌污染,每日均會對細胞培養物進行目視檢查。

Freeze medium
作為冷凍保存培養基,我們使用完全生長培養基(含 FBS)+ 10% DMSO 以確保解凍後的存活率,或使用 CM-1 (Cytion 型號 800100),該培養基含有經優化的滲透保護劑和代謝穩定劑,可提升細胞恢復率並減輕冷凍誘導的壓力。
Storage conditions

若需長期保存,請將試管置於溫度約為 −150 至 −196 °C 的氣相液氮中。僅在轉移至液氮之前,可將試管暫時存放於 −80 °C 環境中,作為短期過渡步驟。

Shipping conditions

冷凍保存的細胞系會以乾冰冷藏,並裝於經驗證的隔熱包裝中,包裝內含有足夠的冷媒,以確保在運輸過程中溫度維持在約 −78 °C。收到貨物後,請立即檢查容器,並盡快將試管轉移至適當的儲存場所。

08Donor

Donor age
40年